NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma

Liu, Shangwen; Ma, Xin; Ai, Qing; Huang, Qingbo; Shi, Taoping; Zhu, Mingyang; Wang, Qianqian; Zhang, Xu

doi:10.1016/j.urolonc.2011.07.006

Cited by 40 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48,50 If transfected with Hes1 siRNA, clear cell renal cell carcinoma cells have a significant change in PTEN level and reduced invasiveness. 51 In addition, Hes1 is required to promote Snail-dependent EMT in HK-2 cells that are cultured in high glucose conditions. 52…”

Section: Overview Of Hes1 Factormentioning

confidence: 99%

“…23 Aberrant Notch-Hes1 pathway is observed in invasive cells which undergo EMT process. [48][49][50][51] In dormant cancer cells, Notch-Hes1 activation can be www.taylorandfrancis.comdetected. 64,65 Above all, the Notch-Hes1 signaling pathway may play a functional role in self-renewal, CSCs maintenance and tumor progression.…”

Section: Canonical Notch Signaling Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

Hes1: a key role in stemness, metastasis and multidrug resistance

Liu¹,

Dai²,

Du³

2015

Cancer Biology & Therapy

162

116

View full text Add to dashboard Cite

Section: Overview Of Hes1 Factormentioning

confidence: 99%

Section: Canonical Notch Signaling Pathwaymentioning

confidence: 99%

Hes1: a key role in stemness, metastasis and multidrug resistance

Liu¹,

Dai²,

Du³

2015

Cancer Biology & Therapy

162

116

View full text Add to dashboard Cite

“…Surgery is the gold standard for localized RCC; however, this strategy provides limited benefits for patients with locally advanced or metastatic RCC; Metastatic RCC is also resistant to chemotherapy and radiotherapy; as such, new therapeutic targets should be developed. In RCC research, several genetic biomarkers, including mRNAs, such as HIF1α [4], Von Hippel-Lindau gene(VHL) [4], NOTCH1 [5], S100A6 [6], and E2F1 [7], and microRNAs (miRs), such as miR-21 [8], miR-221 [9] and miR-30a [10], have been used. Long non-coding RNAs (lncRNAs) have also been extensively investigated because of their clinical usefulness and biological properties in diagnosis, prognosis, and treatment.…”

Section: Introductionmentioning

confidence: 99%

LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis

Chen

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis of different long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC). A total of 14 eligible studies, including 10 on clinicopathological features, 11 on prognosis, and 3 on diagnosis were identified. Results revealed that metastasis-associated lung adenocarcinoma transcript 1(MALAT1) expression was associated with tumor stage (odds ratio [OR], 3.46; 95% confidence interval [CI], 1.63-7.36; p=0.001). The high expression of MALAT1 could be considered a biomarker of the early detection of lymph node metastasis and predictor of poor survival in RCC patients, who likely manifested short overall survival (OS; hazard ratio [HR], 2.97; 95% CI, 1.68-5.28; p<0.001). For diagnostic value, the pooled result showed that lncRNA maintained a sensitivity of 0.89 and specificity of 0.91 in RCC diagnosis, The area under the curve of 0.94 (95% CI, 0.92-0.96) for lncRNA in RCC diagnosis also indicated a significant advantage over other biomarkers. Our systematic review and meta-analysis demonstrated that lncRNAs could be considered biomarkers to detect lymph node metastasis and distant metastasis in early stages. LncRNAs could function as potential prognostic markers in RCC. LncRNAs could also display high accuracy for RCC diagnosis.

show abstract

“…Protein extraction and Western-blot analysis were performed using standard techniques described previously [37] and in Supplementary Data.…”

Section: Methodsmentioning

confidence: 99%

Elevated S100A6 (calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma

Lyu

et al. 2015

Oncotarget

Self Cite

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is often resistant to existing therapy. We found elevated S100A6 levels in ccRCC tissues, associated with higher grade pathological features and clinical stages in ccRCC patients. Knockdown of S100A6 inhibited cell proliferation in vitro and tumor growth in vivo. Gene expression profiling suggests a novel function of S100A6 in suppressing apoptosis, as well as a relationship between S100A6 and CXCL14, a pro-inflammatory chemokine. We suggest that the S100A6/CXCL14 signaling pathway is a potential therapeutic target in ccRCC.

show abstract

NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma

Cited by 40 publications

References 23 publications

Hes1: a key role in stemness, metastasis and multidrug resistance

Hes1: a key role in stemness, metastasis and multidrug resistance

LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis

Elevated S100A6 (calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma

Contact Info

Product

Resources

About